Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Samotolisib - Eli Lilly and Company

Drug Profile

Samotolisib - Eli Lilly and Company

Alternative Names: LY 3023414

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Sarah Cannon Research Institute
  • Developer Eli Lilly and Company; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Imidazoles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 21 Apr 2022 Eli Lilly completes a phase I trial in cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT01655225)
  • 23 Mar 2022 Eli Lilly and Company completes a phase II trial in Endometrial cancer (Second-line therapy or greater) in USA (NCT02549989)
  • 17 Apr 2020 Eli Lilly completes a phase II trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (PO) (NCT02407054)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top